Angiotensin II (medication)

Angiotensin II (Ang II) is a medication that is used to treat hypotension resulting from septic shock or other distributive shock. It is a synthetic vasoconstrictor peptide that is identical to human hormone angiotensin II[1] and is marketed under the brand name Giapreza. The Food and Drug Administration approved the use of angiotensin II in December 2017 to treat low blood pressure resulting from septic shock.[2]

Angiotensin II
Clinical data
Trade namesGiapreza
AHFS/Drugs.comProfessional Drug Facts
Routes of
administration		Intravenous injection
Drug classVasoconstrictor
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein bindingNone
MetabolismProteolysis by glutamyl aminopeptidase, angiotensin converting enzyme 2
MetabolitesAngiotensin III, angiotensin-(1-7)
Elimination half-lifeLess than one minute (IV administration)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC50H71N13O12
Molar mass1046.197 g·mol−1
3D model (JSmol)

Medical uses

Angiotensin II is a vasoconstrictor used to increase blood pressure in adults with septic or other distributive shock. Angiotensin II is a naturally occurring hormone secreted as part of the renin-angiotensin system that results in powerful systemic vasoconstriction.[3][4] The vasopressor effects of angiotensin have been studied since it was first isolated in the late 1930s.[5] Vasopressors are defined as agents that combat vasodilatory shock by inducing peripheral vasoconstriction. Commonly used vasopressors include catecholamine (e.g., dopamine, norepinephrine, epinephrine) and non-catecholamine (e.g., vasopressin). but these agents are not always effective in reversing vasodilatory shock, and their use can be associated with significant side effects including limb ischemia and cardiac arrhythmia. Angiotensin II is as a treatment option that can increase blood pressure and allow catecholamine dose reductions.

Angiotensin II must be administered as an intravenous infusion diluted in 0.9% sodium chloride prior to use. The recommended starting dosage of angiotensin II is 20 nanograms (ng)/kg/min via continuous intravenous infusion. Administration through a central venous line is recommended. Monitor blood pressure response and titrate angiotensin II every 5 minutes by increments of up to 15 ng/kg/min as needed to achieve or maintain target blood pressure.[6]

Adverse effects

Angiotensin II treated patients are at an increased risk of thromboembolic events. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received angiotensin II compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)].[7] It is recommended that patients be on concurrent venous thromboembolism prophylaxis. Other adverse reactions include thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.[6]

Angiotensin II acts on Angiotensin receptor (AT1) on presynaptic adrenergic nerves → release of catecholamine → excessive catecholamine can be harmful as it can cause myocyte necrosis.[8][9]

Interactions

Angiotensin II receptor blockers, as their name implies, block the action of angiotensin II at its receptors and therefore may reduce its effects. ACE inhibitors, on the other hand, may increase its effects.[6][10]

gollark: Call tech support asking for TempleOS help.
gollark: Sending it to "friends" was just an initial testing phase.
gollark: This "innocent" girl was preparing for a strike against all the things the country holds dear.
gollark: Hack the government with the while true do alert thing. They'll never know what hit them.
gollark: It was in the news.

References
  1. Kaufman MB (March 2018). "Pharmaceutical Approval Update". P & T. 43 (3): 141–170. PMC 5821238. PMID 29491694.
  2. "FDA approves drug to treat dangerously low blood pressure". United States Food and Drug Administration. 21 December 2017.
  3. Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R, Miller RR, Hirshberg EL, Grissom CK, Morris AH (March 2013). "Survival after shock requiring high-dose vasopressor therapy". Chest. 143 (3): 664–671. doi:10.1378/chest.12-1106. PMC 3590882. PMID 22911566.
  4. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG (October 2014). "Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study". Critical Care. 18 (5): 534. doi:10.1186/s13054-014-0534-9. PMC 4212099. PMID 25286986.
  5. Bradley SE, Parker B (November 1941). "THE HEMODYNAMIC EFFECTS OF ANGIOTONIN IN NORMAL MAN". The Journal of Clinical Investigation. 20 (6): 715–9. doi:10.1172/JCI101265. PMC 435102. PMID 16694877.
  6. "Giapreza Highlights of Prescribing Information" (PDF). La Jolla Pharmaceutical.
  7. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. (August 2017). "Angiotensin II for the Treatment of Vasodilatory Shock" (PDF). The New England Journal of Medicine. 377 (5): 419–430. doi:10.1056/NEJMoa1704154. PMID 28528561.
  8. Liaudet, Lucas; Calderari, Belinda; Pacher, Pal (2014-11-01). "Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity". Heart Failure Reviews. 19 (6): 815–824. doi:10.1007/s10741-014-9418-y. ISSN 1573-7322.
  9. Liaudet, Lucas; Calderari, Belinda; Pacher, Pal (2014-11-01). "Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity". Heart Failure Reviews. 19 (6): 815–824. doi:10.1007/s10741-014-9418-y. ISSN 1573-7322.
  10. Professional Drug Facts on angiotensin II.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.